A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy - Trial NCT06110663
Access comprehensive clinical trial information for NCT06110663 through Pure Global AI's free database. This Phase 3 trial is sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd. and is currently Not yet recruiting. The study focuses on Non-Small Cell Lung Cancer. Target enrollment is 314 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Timeline & Enrollment
Phase 3
Dec 30, 2023
Feb 28, 2025
Primary Outcome
Progression-free Survival (PFS) evaluated by Independent Review Committee (IRC)
Summary
HS-10241, an oral and highly selective MET-TKI, may contribute to overcoming common acquired
 MET-based resistance mechanisms following prior EGFR-TKI monotherapy. This study is conducted
 to evaluate the efficacy and safety of HS-10241 combined with Almonertinib versus
 platinum-based chemotherapy in NSCLC with MET amplification after failure of EGFR-TKI
 treatment.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06110663
Non-Device Trial